Assertio Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Assertio Therapeutics
ASRT Stock  USD 0.72  0.01  1.37%   
Assertio Therapeutics financial statements provide useful quarterly and yearly information to potential Assertio Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Assertio Therapeutics financial statements helps investors assess Assertio Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Assertio Therapeutics' valuation are summarized below:
Gross Profit
88.4 M
Profit Margin
(0.54)
Market Capitalization
69.6 M
Enterprise Value Revenue
0.0694
Revenue
125.8 M
There are currently one hundred twenty fundamental signals for Assertio Therapeutics that can be evaluated and compared over time across rivals. All traders should validate Assertio Therapeutics' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 71 M in 2025. Enterprise Value is likely to drop to about 60.9 M in 2025

Assertio Therapeutics Total Revenue

128.3 Million

Check Assertio Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Assertio Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.5 M, Total Revenue of 128.3 M or Gross Profit of 111.9 M, as well as many indicators such as Price To Sales Ratio of 0.63, Dividend Yield of 0.0 or PTB Ratio of 1.35. Assertio financial statements analysis is a perfect complement when working with Assertio Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Assertio Therapeutics Correlation against competitors.
For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.

Assertio Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets335.7 M284.7 M535.3 M
Very volatile
Short and Long Term Debt Total36.9 M38.8 M335 M
Pretty Stable
Total Current Liabilities74.2 M114.7 M116.3 M
Pretty Stable
Property Plant And Equipment Net556.7 K586 K5.8 M
Slightly volatile
Accounts Payable15.6 M14.7 M24.2 M
Pretty Stable
Non Current Assets Total78.1 M82.2 M329.5 M
Very volatile
Net Receivables27.5 M54.1 M42.3 M
Slightly volatile
Common Stock Shares Outstanding100 M95.3 M33.1 M
Slightly volatile
Liabilities And Stockholders Equity335.7 M284.7 M535.3 M
Very volatile
Other Current Assets10.9 M10.1 M17.5 M
Slightly volatile
Total Liabilities240.6 M163.7 M382.6 M
Very volatile
Total Current Assets136.2 M202.5 M198.2 M
Pretty Stable
Short Term Debt1 M1.1 M104.6 M
Pretty Stable
Cash79.3 M50.6 M121.4 M
Slightly volatile
Cash And Short Term Investments96 M100.1 M129.4 M
Slightly volatile
Non Current Liabilities Total46.5 M49 M258.7 M
Pretty Stable
Other Stockholder Equity833.9 M794.2 M334.7 M
Slightly volatile
Common Stock7.7 K8.1 K110 M
Slightly volatile
Other Assets1.091.1526.2 M
Pretty Stable
Property Plant Equipment962.5 K1 M6 M
Slightly volatile
Common Stock Total Equity11.1 K11.7 K112.7 M
Slightly volatile
Property Plant And Equipment Gross5.7 M5.1 M6.8 M
Pretty Stable
Other Liabilities29.7 M23.8 M34.4 M
Pretty Stable
Inventory40.2 M38.3 M14.2 M
Slightly volatile
Long Term Investments229.1 K241.2 K12.1 M
Slightly volatile
Non Current Liabilities Other5.2 M5.5 M27.9 M
Pretty Stable
Capital Surpluse552.7 M526.4 M254.9 M
Slightly volatile
Deferred Long Term Asset Charges39.7 M20.7 M37.2 M
Slightly volatile
Long Term Debt Total402.2 M244.1 M354.2 M
Very volatile
Short and Long Term Debt401.9 K423 K170.3 M
Slightly volatile
Net Invested Capital293.6 M159.7 M550.2 M
Slightly volatile
Capital Stock8.5 K10.3 K7 K
Slightly volatile

Assertio Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue128.3 M125 M203 M
Very volatile
Gross Profit111.9 M85.7 M176.3 M
Very volatile
Other Operating Expenses135.7 M149.4 M204.8 M
Pretty Stable
Total Operating Expenses119.2 M110.2 M178.1 M
Pretty Stable
Depreciation And Amortization26.2 M32.5 M43.1 M
Pretty Stable
Selling General Administrative100.7 M75.1 M106.4 M
Pretty Stable
Selling And Marketing Expenses3.8 M4 M4.7 M
Slightly volatile
Interest Income3.1 M3.2 M31.9 M
Slightly volatile
Reconciled Depreciation45.8 M25.8 M77.6 M
Slightly volatile

Assertio Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow64.4 M73.4 M98 M
Very volatile
Depreciation26.9 M25.8 M43.8 M
Pretty Stable
Stock Based Compensation9.1 M5 M8.7 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.630.66414.8322
Slightly volatile
Days Sales Outstanding15015891.9422
Slightly volatile
Average Payables1.9 M2.9 M2.9 M
Pretty Stable
Stock Based Compensation To Revenue0.03540.04010.0449
Pretty Stable
Capex To Depreciation0.02430.02560.3568
Slightly volatile
EV To Sales0.540.56995.1214
Slightly volatile
Inventory Turnover1.981.0242.5668
Very volatile
Days Of Inventory On Hand320356264
Pretty Stable
Sales General And Administrative To Revenue0.410.390.513
Pretty Stable
Average Inventory2.6 M3.5 M3.7 M
Very volatile
Research And Ddevelopement To Revenue0.02910.03060.1441
Slightly volatile
Capex To Revenue0.00450.00470.0244
Slightly volatile
Cash Per Share1.01.05028.9859
Slightly volatile
Intangibles To Total Assets0.410.28260.4637
Slightly volatile
Current Ratio3.341.76612.2319
Pretty Stable
Receivables Turnover2.192.3095.2304
Slightly volatile
Capex Per Share0.00970.01020.2053
Pretty Stable
Average Receivables528.6 K333.7 K331.6 K
Very volatile
Revenue Per Share1.251.311611.054
Slightly volatile
Interest Debt Per Share0.410.434715.3451
Pretty Stable
Debt To Assets0.240.13630.3499
Pretty Stable
Graham Number22.0514.2924.7228
Slightly volatile
Operating Cycle489515335
Pretty Stable
Long Term Debt To Capitalization0.340.24270.4551
Very volatile
Total Debt To Capitalization0.340.24270.469
Very volatile
Quick Ratio1.361.43211.9951
Pretty Stable
Net Income Per E B T1.180.99761.7444
Pretty Stable
Cash Ratio0.420.44111.9841
Slightly volatile
Days Of Inventory Outstanding320356264
Pretty Stable
Days Of Sales Outstanding15015891.9422
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.141.0002
Pretty Stable
Fixed Asset Turnover22421376.0947
Slightly volatile
Debt Ratio0.240.13630.3499
Pretty Stable
Price Sales Ratio0.630.66414.8322
Slightly volatile
Asset Turnover0.290.43890.405
Pretty Stable
Gross Profit Margin1.30.68610.9257
Pretty Stable

Assertio Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap71 M74.7 M357.5 M
Slightly volatile
Enterprise Value60.9 M64.1 M407.5 M
Slightly volatile

Assertio Fundamental Market Drivers

Forward Price Earnings14.9925
Cash And Short Term Investments100.1 M

Assertio Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Assertio Therapeutics Financial Statements

Assertio Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Assertio Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Assertio Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Assertio Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue77.5 M42 M
Total Revenue125 M128.3 M
Cost Of Revenue39.2 M21 M
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.39  0.41 
Research And Ddevelopement To Revenue 0.03  0.03 
Revenue Per Share 1.31  1.25 
Ebit Per Revenue(0.20)(0.21)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY